Shanghai Zhisheng Technology Co., Ltd.

Zhisheng Technology is committed to applying cutting-edge artificial intelligence and brain science technologies to address brain health diseases. The company's core R&D team comprises neuroscientists from the Swiss Federal Institute of Technology Lausanne (EPFL), a French engineering school, and top clinical neurologists. Innovatively leveraging AI-based eye-tracking technology, Zhisheng has developed a brain cognitive function assessment technology based on camera-based eye tracking, creating the first AI eye-tracking 'digital biomarker' product in China. Around Alzheimer's disease, depression, and childhood ADHD, the company has built comprehensive solutions covering screening, diagnosis, intervention, treatment, and insurance payment. The company's technology products have served multiple well-known domestic medical institutions (such as Huashan Hospital, Ruijin Hospital), enterprises and insurance organizations (such as Roche Pharmaceuticals, Pacific Insurance), and government entities (such as Shanghai and Nanning). The company has won the Singapore Lee Kuan Yew Global AI Innovation Award and was recognized as one of the most promising returnee entrepreneurship teams in 2022.